Case study

Supporting an EU pharmaceutical company to an MHRA WDA

An EU pharmaceutical company needed a UK Wholesale Distribution Authorisation to supply the UK market after Brexit.

Client
Established pharmaceutical company operating across Europe
Outcome
WDA licence number issued on the day of the MHRA inspection

The challenge

The client had a proven operating model across Europe but no UK authorisation. To supply UK customers after Brexit, it needed an MHRA Wholesale Distribution Authorisation. That meant a Quality Management System built to MHRA expectations, a complete set of procedures, and a successful inspection.

Our approach

We supported the client end to end, from interpreting the requirements to building the documentation and systems behind the application:

  • A Quality Management System tailored to MHRA expectations and the client’s real operations
  • Standard operating procedures covering receipt and storage, temperature monitoring, record-keeping, training and deviation handling
  • Working through differences where the client’s group-wide ways of documenting things differed from UK expectations. We agreed a path with the client’s stakeholders, using evidence-based recommendations.

The result

The client received its WDA licence number on the day of the MHRA inspection. It could start distributing in the UK straight away, opening a new revenue stream.

“We're very pleased with the work done to help us in obtaining our WDA licence number.”

— Country Director